Indications -- Psoriasis/Chronic Inflammation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (379)	3/19/2003 11:15:53 AM
From: keokalani'nui	of 631

Angiotech announces positive Phase 1 Psoriasis results Wednesday March 19, 9:01 am ET VANCOUVER, March 19 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals Inc. (NASDAQ:ANPI - News; TSX:ANP - News) today announced positive results in its Pilot Phase 1 Psoriasis Study. The National Cancer Institute completed a study evaluating the systemic use of PAXCEED(TM) (a Cremophor® EL-free paclitaxel formulation) in a challenging group of patients with severe psoriasis. Eligible patients had a PASI (Psoriasis Area and Severity Index) Score of 20 or greater (severe disease), and had been treated with at least two other systemic agents. No concomitant therapies were allowed during the trial. Patients were treated with either 75 mg/m2 of PAXCEED(TM) every four weeks for six treatments or a second protocol of 37.5 mg/m2 every two weeks for three treatments followed by six doses of 50 mg/m2 every two weeks. Nine patients completed the study. All patients had a positive response to PAXCEED(TM). In the optimal dose regime group utilizing 75 mg/m2 monthly, the average PASI score improvement was 64 percent. The study also demonstrated that once the patients came off therapy, there was no rapid rebound effect or exaggerated recurrence of disease, as typically displayed with traditional immunosuppressive agents or steroids. The safety and side effect profile was excellent and consistent with all other previous systemic PAXCEED(TM) programs. Angiotech is currently enrolling patients in a Phase 2 rheumatoid arthritis study using PAXCEED(TM) and results are expected to be available in 2004. Angiotech intends to seek a strategic partnership for its systemic PAXCEED(TM) program subject to the completion of the rheumatoid arthritis trial. Paclitaxel is a potent, multifunctional, small molecule anti- inflammatory, believed to be an ideal compliment to the new generation large molecule therapies.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next